Table 1 Baseline characteristics of patients with primary and secondary GI MCL.

	Primary GI MCL, n	%	Secondary GI MCL, n	%	P value
Age					0.53
≤60 y	10	45.5	30	38.0
>60 y	12	54.5	49	62.0
Sex					0.75
Male	19	86.4	66	83.5
Female	3	13.6	13	16.5
ECOG performance status					0.68^a
<2	18	94.7	67	89.3
≥2	1	5.3	8	10.7
Missing	3		4
B symptoms					0.76^a
Yes	3	14.3	15	19.2
No	18	85.7	63	80.8
Missing	1		1
Sites of GI involvement					0.43
Upper GI trac	4	18.2	7	8.9
Lower GI tract	14	63.6	59	74.7
Both upper and lower GI tract	4	18.2	13	16.5
GI lesion type					0.12
Single polyp	3	13.6	13	17.3
Multiple polyps	14	63.6	25	33.3
Mass lesions	2	9.1	16	21.3
Ulceration, erosion, or nodular lesion	3	13.6	17	22.7
Random biopsy	0	0	4	5.3
Missing	0		4
Histologic subtype					1.00^a
Classic MCL	21	95.5	73	94.8
Blastoid variant	1	4.5	4	5.2
Missing	0		2
LDH					0.03^a
Normal	14	100.0	51	71.8
Elevated	0		20	28.2
Missing	8	0.0	8
WBC count					0.33^a
Normal	12	85.7	51	70.8
Elevated	2	14.3	21	29.2
Missing	8		7
MIPI risk					0.07
Low	10	71.4	29	40.8
Intermediate	1	7.1	25	35.2
High	3	21.4	17	23.9
Missing	8		8

^aFisher’s exact test. Others were Chi-square test.
Abbreviations: GI gastrointestinal, MCL mantle cell lymphoma, ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, WBC white blood cell, MIPI MCL international prognostic index.

Quick links

Search